Drug
Colestipol
Colestipol is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_2
2
33%
Ph phase_3
2
33%
Ph phase_4
1
17%
Phase Distribution
1
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (16.7%)
Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)
Trials by Status
completed583%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
NCT02400476
terminatedphase_1
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
NCT02263547
completedphase_2
Sorbent Therapy of the Cutaneous Porphyrias
NCT01422915
completedphase_3
Familial Atherosclerosis Treatment Study
NCT00000512
completedphase_4
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
NCT00203476
Clinical Trials (6)
Showing 6 of 6 trials
NCT02400476Phase 2
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
NCT02263547Phase 1
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
NCT01422915Phase 2
Sorbent Therapy of the Cutaneous Porphyrias
NCT00000512Phase 3
Familial Atherosclerosis Treatment Study
NCT00203476Phase 4
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
NCT00000599Phase 3
Cholesterol-Lowering Atherosclerosis Study (CLAS)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6